A Phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: Results of an Indian population subanalysis

Indian Journal of Cancer

Volumn 50, Issue 4, 2013, Pages 285-291

  Maru, A ^a   Gangadharan, V P ^b   Desai, C J ^c   Mohapatra, R K ^d   Carides, A D ^e  

^a S K Soni Hospital   (India)

^b Lakeshore Hospital and Research Centre Ltd   (India)

^c Educational Initiatives Pvt Ltd   (India)

^d Apollo Speciality Hospital   (India)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiemetic therapy; aprepitant; chemotherapy induced nausea and vomiting; fosaprepitant; Indian population; noninferiority

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; FOSAPREPITANT; ONDANSETRON; ANTIEMETICS; MORPHOLINES;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPONATREMIA; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOPHLEBITIS; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; YOUNG ADULT; AGED, 80 AND OVER; CHEMICALLY INDUCED; CLINICAL TRIAL; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INDIA; NAUSEA; NEOPLASMS; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; CISPLATIN; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS;

EID: 84891883311     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.123580     Document Type: Article

References (14)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Antiemesis. V3.2011. Available from: Http://www.nccn.org/ professionals/physician-gls/f-guidelines. asp. [Last accessed on 2012 Mar 28
2. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-67
3. Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55
4. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-9
5. Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer 2010;18:423-31
6. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30
7. Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol-EASE. J Clin Oncol 2011;29:1495-501
8. Lasseter KC, Gambale J, Jin B, Bergman A, Constanzer M, Dru J, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007;47:834-40
9. Merck. Emend (fosaprepitant dimeglumine) for injection. Prescribing Information 2008. Available from: Http://www.merck.com/ product/usa/pi- circulars/e/emend-iv/emend-iv-pi.pdf. [Last accessed on 2012 Mar 28
10. Zeng WL, Chan A. Clinical predictors of chemotherapy induced nausea and vomiting in head and neck cancer patients on cisplatin regimens. Proceeding from the National Undergraduate Research Opportunities Programme Congress 2010
11. Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K. Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 2010;101:2455-61
12. Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 2009;113:529-35
13. Biswas A, Tandon R, Chakrabarti A, Bhattacharya SK. Comparative evaluation of ondansetron vs metoclopromide/dexamethasone combination as antiemetic in cisplatin based cancer chemotherapy. Indian J Med Paediatr Oncol 1996;17:196-9
14. Hassan BA, Yusoff ZB. Negative impact of chemotherapy on breast cancer patients QOL-utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev 2010;11:1523-7